Page 161 - Haematologica3

Melphalan dose pre-transplant in MM
lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicen- tre, phase 3 trial. Lancet Oncol. 2015;16(16): 1617-1629.
5. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexametha- sone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311-1320.
6. Gay F, Oliva S, Petrucci MT, et al. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. Leukemia. 2017;31(8):1727-1734.
7. Auner HW, Szydlo R, Hoek J, et al. Trends in autologous hematopoietic cell transplanta- tion for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant. 2015;50(2):209-215.
8. Costa LJ, Zhang MJ, Zhong X, et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant. 2013;19(11):1615-1624.
9. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced- intensity autologous stem cell transplanta- tion in elderly patients with multiple myelo- ma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-1218.
10. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves sur- vival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104(10):3052-3057.
11. Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous trans- plantation in newly diagnosed multiple myeloma patients included in the PETHE- MA/GEM2000 study. Haematologica. 2010;95(11):1913-1920.
12. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regi- mens for peripheral blood stem cell trans- plantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99(3):731-735.
13. Palumbo A, Bringhen S, Bruno B, et al. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood. 2010;115(10):1873-1879.
14. Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B. Low-risk intensive therapy for multiple myeloma with combined autolo- gous bone marrow and blood stem cell sup- port. Blood. 1992;80(7):1666-1672.
15. Shah N, Callander N, Ganguly S, et al. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21(7):1155-1166.
16. Giralt S. 200 mg/m(2) melphalan--the gold standard for multiple myeloma. Nat Rev Clin Oncol. 2010;7(9):490-491.
17. Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in eld- erly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114(3):600- 607.
18. Badros A, Barlogie B, Siegel E, et al. Results
of autologous stem cell transplant in multi- ple myeloma patients with renal failure. Br J Haematol. 2001;114(4):822-829.
19. Sweiss K, Patel S, Culos K, Oh A, Rondelli D, Patel P. Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival. Bone Marrow Transplant. 2016;51(10):1337- 1341.
20. Katragadda L, McCullough LM, Dai Y, et al. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in mul- tiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience. Clin Transplant. 2016;30(8):894-900.
21. Dhakal B, Nelson A, Guru Murthy GS, et al. Autologous hematopoietic cell transplanta- tion in patients with multiple myeloma: effect of age. Clin Lymphoma Myeloma Leuk. 2017;17(3):165-172.
22. Gertz MA, Lacy MQ, Dispenzieri A, et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2007;39(10):605-611.
23. Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol. 2008;83(8):614-617.
24. Garderet L, Beohou E, Caillot D, et al. Upfront autologous stem cell transplanta- tion for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. Haematologica. 2016;101(11):1390- 1397.
25. Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28(33):4976-4984.
26. Muchtar E, Dingli D, Kumar S, et al. Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplant. 2016;51(11):1449-1455.
27. Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and fol- low-up. Ann Oncol. 2017;28(suppl_4):iv52- iv61.
28. Cavo M, Petrucci MT, Di Raimondo F, et al. Upfront single versus double autologous stem cell transplantation for newly diag- nosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02/HO95 MM Trial). Blood. 2016;128(22):991.
29. Nath CE, Shaw PJ, Trotman J, et al. Population pharmacokinetics of melphalan in patients with multiple myeloma undergo- ing high dose therapy. Br J Clin Pharmacol. 2010;69(5):484-497.
30. Shaw PJ, Nath CE, Lazarus HM. Not too lit- tle, not too much-just right! (better ways to give high dose melphalan). Bone Marrow Transplant. 2014;49(12):1457-1465.
31. Nath CE, Trotman J, Tiley C, et al. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. Br J Clin Pharmacol. 2016;82(1):149-159.
32. Merz M, Neben K, Raab MS, et al. Autologous stem cell transplantation for eld-
erly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol. 2014;25(1):189-195.
33. Bashir Q, Shah N, Parmar S, et al. Feasibility of autologous hematopoietic stem cell trans- plant in patients aged >/=70 years with mul- tiple myeloma. Leuk Lymphoma. 2012;53(1):118-122.
34. Auner HW, Garderet L, Kroger N. Autologous haematopoietic cell transplanta- tion in elderly patients with multiple myelo- ma. Br J Haematol. 2015;171(4):453-462.
35. Straka C, Liebisch P, Salwender H, et al. Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a random- ized trial. Haematologica. 2016;101(11): 1398-1406.
36. Engelhardt M, Ihorst G, Caers J, Gunther A, Wasch R. Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents? Haematologica. 2016;101(11):1276-1278.
37. Zweegman S, Engelhardt M, Larocca A, EHA SWG on "Aging and Hematology". Elderly patients with multiple myeloma: towards a frailty approach? Curr Opin Oncol. 2017;29(5):315-321.
38. Engelhardt M, Domm AS, Dold SM, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910- 921.
39. Bruno B, Auner HW, Gahrton G, et al. Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting). Leuk Lymphoma. 2016;57(6):1256-1268.
40. Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068-2074.
41. Roussel M, Moreau P, Huynh A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood. 2010;115(1):32-37.
42. Blanes M, Lahuerta JJ, Gonzalez JD, et al. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant. 2013;19(1):69-74.
43. Rodriguez TE, Hari P, Stiff PJ, Smith SE, Sterrenberg D, Vesole DH. Busulfan, mel- phalan, and bortezomib versus high-dose melphalan as a conditioning regimen for autologous hematopoietic stem cell trans- plantation in multiple myeloma. Biol Blood Marrow Transplant. 2016;22(8): 1391-1396.
44. Nieto Y, Valdez BC, Pingali SR, et al. High- dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myelo- ma: a phase 2 trial and matched-pair com- parison with melphalan. Lancet Haematol. 2017;4(6):e283-e292.
45. Morgan GJ, Rasche L. Haematological can- cer: Where are we now with the treatment of multiple myeloma? Nat Rev Clin Oncol. 2017;14(8):461-462.
haematologica | 2018; 103(3)
521